Journal article
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications
Schizophrenia research, Vol.79(2), pp.281-288
2005
DOI: 10.1016/j.schres.2005.04.010
PMID: 15964743
Abstract
There is a growing concern regarding the propensity of second generation antipsychotics (SGAs) to induce weight gain and metabolic adverse effects. Recent consensus guidelines have recommended assessment and monitoring procedures to appropriately detect and manage these adverse effects. This study addresses the appreciation and readiness of clinicians to implement management guidelines for these adverse effects. Respondents indicated awareness of the risks of treatment with SGAs. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice.
Details
- Title: Subtitle
- Clinicians' recognition of the metabolic adverse effects of antipsychotic medications
- Creators
- Peter F Buckley - Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912-3800, United StatesDel D MillerBeth SingerJohn ArenaEdna M Stirewalt
- Resource Type
- Journal article
- Publication Details
- Schizophrenia research, Vol.79(2), pp.281-288
- Publisher
- Elsevier B.V
- DOI
- 10.1016/j.schres.2005.04.010
- PMID
- 15964743
- ISSN
- 0920-9964
- eISSN
- 1573-2509
- Language
- English
- Date published
- 2005
- Academic Unit
- Psychiatry
- Record Identifier
- 9984003441802771
Metrics
24 Record Views